Trial Profile
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Losartan
- Indications Hypertension
- Focus Therapeutic Use
- Acronyms BeniVICTOR
- Sponsors Daiichi Sankyo Inc
- 01 Jan 2011 Results were published in the Journal of Postgraduate Medicine.
- 01 Oct 2010 Results were presented in a late breaker session at the 23rd Scientific Meeting of the International Society of Hypertension (ISH).
- 01 Oct 2010 Trial acronym and long name added, as reported in a Daiichi Sankyo media release.